May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Twenty–Four Hour Additive Reduction of Intraocular Pressure by Brinzolamide (Ophthalmic Solution) in Latanoprost–Treated Glaucoma Eyes
Author Affiliations & Notes
  • K. Abe
    Ophthalmology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan
  • K. Kashiwagi
    Ophthalmology, University of Yamanashi, Yamanashi, Japan
  • Footnotes
    Commercial Relationships  K. Abe, None; K. Kashiwagi, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 449. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Abe, K. Kashiwagi; Twenty–Four Hour Additive Reduction of Intraocular Pressure by Brinzolamide (Ophthalmic Solution) in Latanoprost–Treated Glaucoma Eyes . Invest. Ophthalmol. Vis. Sci. 2006;47(13):449.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate whether brinzolamide ophthalmic solution reduces intraocular pressure (IOP) throughout the day in latanoprost–treated eyes with primary open angle glaucoma (POAG).

Methods: : A prospective, nonrandomized clinical trial design was employed. Patients with POAG administered latanoprost ophthalmic solution once a day (at 9 p.m.) in both eyes for more than four weeks and they were admitted for the first around–the–clock IOP measurement. IOP was measured at 3, 6, 8, 10, 12 a.m., and at 2, 4, 6, 8, 10, 12 p.m. using a Goldmann applanation tonometer without discontinuing ophthalmic solution. Eye showing higher IOP at 10 a.m was chosen as an experimental eye and brinzolamide ophthalmic solution was additionally administered this eye twice a day (at 7 a.m. and 7p.m.). The other eye administered only latanoprost as before (control eye). Four to eight weeks later, the patients were admitted again for the second around–the–clock IOP measurement. IOP measurement was repeated with a completely same fashion as before.

Results: : Seven patients (60.0±9.2 years old) consisting of four male and three female completed the protocol. Mean IOP values calculated from all IOP values during the first admission were 14.8±2.3mmHg in the experimental eye and 13.5±3.3mmHg in the control eye, respectively, and this IOP difference was not significant. Mean IOP values calculated from the second admission were 13.2±2.2mmHg in the experimental eye and 13.8±3.0mmHg in the control eye, respectively. Brinzolamide ophthalmic solution significant reduced mean IOP in experimental eyes (p<0.01), while mean IOP in the control eye was not changed significantly. This significantly additional IOP reduction by brinzolamide ophthalmic solution was observed throughout the day even at night time except at 6 a.m. and 6 p.m. when just before administration of brinzolamide ophthalmic solution.

Conclusions: : Brinzolamide ophthalmic solution successfully reduces IOP throughout the day in glaucoma eyes with previously treated with latanoprost ophthalmic solution.

Keywords: pharmacology • intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.